Co-Authors
This is a "connection" page, showing publications co-authored by SIMRIT PARMAR and KRINA PATEL.
Connection Strength
0.548
-
Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells. Cells. 2023 07 18; 12(14).
Score: 0.232
-
Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther. 2021 03; 27(3):243.e1-243.e6.
Score: 0.048
-
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275.
Score: 0.043
-
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant. 2019 05; 25(5):1039-1044.
Score: 0.042
-
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575.
Score: 0.038
-
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017 Jun; 4(6):e283-e292.
Score: 0.038
-
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.
Score: 0.037
-
Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. 2016 10; 91(10):E442-7.
Score: 0.036
-
Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur J Haematol. 2016 Oct; 97(4):342-7.
Score: 0.035